Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...
Pharmabiz

Antengene Corporation receives CDE endorsement to begin pivotal phase III CLINCH-3 study of ATG-022

Antengene Corporation receives CDE endorsement to begin pivotal phase III CLINCH-3 study of ATG-022: Shanghai Friday, May 29, 2026, 18:00 Hrs [IST] Antengene Corporation Limited, ...
Morningstar

ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy

Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a ...